Key facts
- This page summarizes Ram Aiyar's Form 4 filing for Korro Bio, Inc. (KRRO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 05 Aug 2026, 16:05.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
No transaction description listed
Additional SEC filing notes
Footnote F1
Represents the mandatory sale of shares of common stock solely to satisfy tax withholding obligations incurred upon vesting and settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan).
Footnote F2
The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $10.57 to $11.055, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request.
Footnote F3
Includes 20,000 shares of common stock issuable upon settlement of a RSU granted under the 2023 Plan that will vest on February 1, 2027 subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through such date.
Footnote F4
Shares held by The Ram Aiyar Irrevocable Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.